Table 2.
Clinical characteristics of Cancer Patients by Health Insurance Coverage, from SEER 2007–2016
| Total | Non-Medicaid Insurance | Medicaid | Uninsured | p-Value* | |
|---|---|---|---|---|---|
| Year of Diagnosis | < 0.001 | ||||
| 2007–2010 | 302,705 | 242,494 (80.1%) | 44,527 (14.7%) | 15,684 (5.2%) | |
| 2011–2013 | 230,397 | 178,237 (77.3%) | 39,321 (17.1%) | 12,839 (5.6%) | |
| 2014–2016 | 234,953 | 182,209 (77.5%) | 45,053 (19.2%) | 7691 (3.3%) | |
| Therapy | < 0.001 | ||||
| Radiation therapy | 294,652 | 233,250 (38.7%) | 49,626 (38.5%) | 11,776 (32.5%) | |
| Chemotherapy | 412,782 | 321,439 (53.3%) | 71,491 (55.5%) | 19,852 (54.8%) | |
| Surgery | 544,696 | 448,781 (74.4%) | 77,056 (59.8%) | 18,859 (52.1%) | |
| Extent of cancer | < 0.001 | ||||
| in situ | 23,904 (3.1%) | 20,640 (3.4%) | 2302 (1.8%) | 962 (2.7%) | |
| Localized | 32,536 (42.4%) | 272,769 (45.2%) | 42,813 (33.2%) | 9784 (27.0%) | |
| Regional | 220,740 (28.7%) | 170,364 (28.3%) | 40,222 (31.2%) | 10,154 (28.0%) | |
| Distant | 198,045 (25.8%) | 139,167 (23.1%) | 43,564 (33.8) | 15,314 (42.3%) | |
| Site of cancer | < 0.001 | ||||
| Colorectal | 9369 (12.2%) | 72,171 (12.0%) | 15,352 (11.9%) | 6167 (17.0%) | |
| Lung | 149,075 (19.4%) | 105,051 (17.4%) | 33,410 (25.9%) | 10,614 (29.3%) | |
| Breast | 343,516 (44.7%) | 285,563 (47.4%) |
49,231 `1 8 .2%) |
8722 (24.1%) | |
| Cervical | 25,714 (3.4%) | 15,329 (2.5%) | 8344 (6.5%) | 2041 (5.6%) | |
| Ovarian | 29,383 (3.8%) | 22,891 (3.8%) | 4688 (3.6%) | 1804 (5.0%) | |
| Urinary/bladder | 43,890 (5.7%) | 82.60 (6.0%) | 5455 (4.2%) | 2180 (6.0%) | |
| Hodgkin lymphoma | 1498 (2.0%) | 11,488 (1.9%) | 2458 (1.9%) | 1034 (2.9%) | |
| Non-Hodgkin lymphoma | 67,807 (8.8%) | 54,192 (9.0%) | 9963 (7.7%) | 3652 (10.1%) |
* p-value were estimated using chi-sq tests